Abstract
Ipilimumab, an immune checkpoint inhibitor, is approved for treatment metastastic melanoma and is a promising agent against other malignancies. There is some preliminary evidence from case reports that ipilimumab treatment may be associated with pulmonary side effects. However, data from prospective studies on ipilimumab-related pulmonary toxicity are still scarce. Serial spirometries and measurements of CO-diffusion capacity (DLCO) in patients with metastatic melanoma before and during treatment with ipilimumab were performed. A reduction from baseline of forced vital capacity (FVC) of ≥ 10%, or ≥ 15% of DLCO was defined as clinically meaningful and indicative for pulmonary toxicity. Of 71 patients included in this study, a clinically meaningful lung function decline was registered in 6/65 (9%), 5/44 (11%), and 9/38 (24%) patients after 3, 6, and 9 weeks of treatment initiation, respectively. Even after adjusting for age, concomitant melanoma treatment, progressive pulmonary metastases, and baseline pulmonary function values, mean ± SD DLCO decreased significantly during follow-up (−4.3% ± 13.6% from baseline, p = 0.033). Only 7% of patients reported respiratory symptoms. Clinically manifest ipilimumab-related pneumonitis was diagnosed only in one patient (1.4%). DLCO decline maybe an early indicator of subclinical pulmonary drug toxicity. Therefore, routine pulmonary function testing including DLCO measurement during treatment might help for risk stratification to screen for ipilimumab-related pneumonitis.
Similar content being viewed by others
Abbreviations
- ARDS:
-
Acute respiratory distress syndrome
- BAL:
-
Broncho-alveolar lavage
- COPD:
-
Chronic obstructive pulmonary disease
- CTLA-4:
-
Cytotoxic T-lymphocyte-associated antigen 4
- DLCO:
-
Diffusion capacity of the lung for carbon monoxide
- FDG-PET/CT:
-
18-Fluorodeoxyglucose positron emission tomography combined with computed tomography
- FVC:
-
Forced vital capacity
- HR-CT:
-
High-resolution CT
- NSCLC:
-
Non-small cell lung cancer
- OR:
-
Odds ratio
- OP:
-
Organizing pneumonia
- PFT:
-
Pulmonary function tests
References
Culver ME, Gatesman ML, Mancl EE, Lowe DK (2011) Ipilimumab: a novel treatment for metastatic melanoma. Ann Pharmacother 45:510–519. doi:10.1345/aph.1P651
Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. doi:10.1056/NEJMoa1003466
Dummer R, Schadendorf D, Ascierto PA, Larkin J, Lebbe C, Hauschild A (2015) Integrating first-line treatment options into clinical practice: what’s new in advanced melanoma? Melanoma Res 25:461–469. doi:10.1097/cmr.0000000000000200
Andrews S, Holden R (2012) Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res 4:299–307. doi:10.2147/cmar.s31873
Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, Nishino M (2015) Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3:1185–1192. doi:10.1158/2326-6066.cir-15-0102
Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L (2009) Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 218:69–70. doi:10.1159/000161122
Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Mazza Stalder J, Speiser DE, Peters S, Michielin O (2012) Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 30:e156–e159. doi:10.1200/jco.2011.39.3298
Wilgenhof S, Morlion V, Seghers AC, Du Four S, Vanderlinden E, Hanon S, Vandenbroucke F, Everaert H, Neyns B (2012) Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res 32:1355–1359
Tissot C, Carsin A, Freymond N, Pacheco Y, Devouassoux G (2013) Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy. Eur Respir J 41:246–247. doi:10.1183/09031936.00107912
Franzen D, Schad K, Dummer R, Russi EW (2013) Severe acute respiratory distress syndrome due to ipilimumab. Eur Respir J 42:866–868. doi:10.1183/09031936.00044113
Langer CJ (2015) Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol 38:422–430. doi:10.1097/coc.0000000000000059
Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH (2015) Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 373:288–290. doi:10.1056/NEJMc1505197
Nishino M, Chambers ES, Chong CR et al (2016) Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol Res 4:289–293. doi:10.1158/2326-6066.cir-15-0267
Nishino M, Ramaiya NH, Awad MM et al (2016) PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 22:6051–6060. doi:10.1158/1078-0432.ccr-16-1320
Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS (2016) Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2:1607–1616. doi:10.1001/jamaoncol.2016.2453
Hodi FS, Lee S, McDermott DF et al (2014) Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:1744–1753. doi:10.1001/jama.2014.13943
Miller MR, Hankinson J, Brusasco V et al (2005) Standardisation of spirometry. Eur Respir J 26:319–338. doi:10.1183/09031936.05.00034805
Macintyre N, Crapo RO, Viegi G et al (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26:720–735. doi:10.1183/09031936.05.00034905
Franzen D, Ciurea A, Bratton DJ, Clarenbach CF, Latshang TD, Russi EW, Kyburz D, Kohler M (2016) Effect of rituximab on pulmonary function in patients with rheumatoid arthritis. Pulm Pharmacol Ther 37:24–29. doi:10.1016/j.pupt.2016.02.002
Heigener D, Reck M (2015) Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer. Expert Rev Anticancer Ther 15:69–83. doi:10.1586/14737140.2015.957187
Linardou H, Gogas H (2016) Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med 4:272. doi:10.21037/atm.2016.07.10
Abdel-Rahman O, Fouad M (2016) Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis 10:183–193. doi:10.1177/1753465816636557
Gounant V, Brosseau S, Naltet C, Opsomer MA, Antoine M, Danel C, Khalil A, Cadranel J, Zalcman G (2016) Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. Lung Cancer 99:162–165. doi:10.1016/j.lungcan.2016.07.010
Fragkou P, Souli M, Theochari M, Kontopoulou C, Loukides S, Koumarianou A (2016) A case of organizing pneumonia (OP) associated with pembrolizumab. Drug Target Insights 10:9–12. doi:10.4137/dti.s31565
Crapo RO, Jensen RL, Wanger JS (2001) Single-breath carbon monoxide diffusing capacity. Clin Chest Med 22:637–649
Epler GR, McLoud TC, Gaensler EA, Mikus JP, Carrington CB (1978) Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N Engl J Med 298:934–939. doi:10.1056/nejm197804272981703
Burton C, Kaczmarski R, Jan-Mohamed R (2003) Interstitial pneumonitis related to rituximab therapy. N Engl J Med 348:2690–2691. doi:10.1056/nejm200306263482619 (discussion-1)
Robert C, Karaszewska B, Schachter J et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30–39. doi:10.1056/NEJMoa1412690
Author contributions
Conception: Daniel Franzen, Karin Schad, Reinhard Dummer, Malcolm Kohler. Data collection: Daniel Franzen, Karin Schad, Benedikt Kowalski, Christian F. Clarenbach. Data analysis and interpretation: Daniel Franzen, Benedikt Kowalski, Roger Stupp, Reinhard Dummer, Malcolm Kohler. Drafting of the article: Daniel Franzen, Karin Schad, Benedikt Kowalski. Critical revision: Roger Stupp, Reinhard Dummer, Malcolm Kohler. Final approval: All authors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Reinhard Dummer received research funding from Novartis, Merck Sharp & Dome (MSD), Bristol-Myers Squibb (BMS), Roche, GlaxoSmithKline (GSK) and has a consultant or advisory board relationship with Novartis, Merck Sharp & Dome, Bristol-Myers Squibb, Roche, GlaxoSmithKline, and Amgen, all outside the submitted work. All other authors report no conflicts of interest that could influence the results of the study.
Ethical approval
The study is in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the local Ethics committee (KEK-ZH 2013-0191) and is registered at ClinicalTrials.gov (NCT02755233).
Informed consent
Written informed consent to participate in the study and to publish the data was given by all subjects included in the study. Particularly, the publication of the CT scan was consented by the individual patient.
Rights and permissions
About this article
Cite this article
Franzen, D., Schad, K., Kowalski, B. et al. Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study. Cancer Immunol Immunother 67, 127–134 (2018). https://doi.org/10.1007/s00262-017-2071-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-017-2071-2